Among women with class I obesity (BMI 30.034.9 kg/m), the pregnancy rate was 17.4% in the semaglutide group versus 25.5% in controls (OR = 0.61, 95% CI 0.390.97, p = 0.035), representing a statistically significant decrease
no discontinuation of treatment and no missed doses), but in fact persistence and adherence are significant problems for actual patients [11, 25]
Note that Empower tirzepatide/niacinamide injections arrive ready to use, not lyophilized
Whether you are just starting or already using a semaglutide weekly injection , understanding the correct dosage schedule is critical for safety, fat loss, and long-term success
Our experienced medical professionals will provide a thorough consultation before treatment